The domestic brain-computer interface (BCI) company NeuroXess has recently declared the successful closure of its Series B funding round, amassing RMB 700 million. This round of financing was co-led by a consortium of institutions, drawing in a host of renowned investors, and continued backing from current shareholders.

The capital raised will be predominantly allocated towards conducting multi-center clinical trials, obtaining regulatory clearance for the comprehensive BCI system, establishing large-scale production facilities at a state-of-the-art factory, advancing the development of next-generation products, and delving into the synergistic integration of BCI and artificial intelligence (AI). NeuroXess aims to propel the widespread adoption of its products in the medical sector within the next two years.

This funding round has garnered significant interest from leading investors across various industries, forming a diverse and high-caliber investment portfolio. The sustained support from existing shareholders underscores the capital market's enduring confidence in NeuroXess and its vision for the future.